Physician profile
Heather Muse
NPI 1972917854
$697.50
in general payments reported to CMS, 2019-2025
15 companies · $250 in 2025
The $250 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $41.05 · 2022: $65.85 · 2023: $154 · 2024: $187 · 2025: $250.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $591.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $590.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $139.08 | 2023-2025 | Invega Sustenna |
| Abbvie INC. | $126.30 | 2023-2025 | |
| Alkermes, INC. | $76.45 | 2025 | Aristada, Lybalvi |
| Novo Nordisk INC | $51.68 | 2025 | Ozempic, Rybelsus |
| Otsuka America Pharmaceutical, INC. | $42.39 | 2022-2025 | Abilify Asimtufii |
| Organon LLC | $40.39 | 2021-2022 | |
| Amgen INC. | $37.22 | 2024 | Repatha, Otezla |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $35.36 | 2022-2024 | Caplyta |
| Lilly USA, LLC | $32.63 | 2021-2024 | Jardiance |
| Renalytix Ai, INC. | $22.54 | 2023 | Kidneyintelx Blood Collection Convenience Kit |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $21.03 | 2024 | Xifaxan |
| Bayer Healthcare Pharmaceuticals INC. | $20.29 | 2023 | |
| Verona Pharma, INC. | $20.23 | 2025 | Ohtuvayre |
| Supernus Pharmaceuticals, INC. | $16.67 | 2024 | Qelbree |
| Esperion Therapeutics, INC. | $15.24 | 2023 | Nexletol |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Heather Muse listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.